Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.
1999
The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pre
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
22
Citations
NaN
KQI